Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.88 |
| ▸ | PTGIR | P43119 | 3/20 | 0.88 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Domitroban SCHEMBL361564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL3380908 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7595949 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9198684 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL9875564 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL361563 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232264 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2232269 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL2923394 | 1.00 | TBXA2R (1.00) | TBXA2RPTGDRPTGIRTBXAS1 | |
| Domitroban SCHEMBL7600963 | 0.99 | TBXA2R (0.98) | TBXA2RPTGDRPTGIRTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8506935-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7550133-B2 | Respiratory drug condensation aerosols and methods of making and using them | ALEXZA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258075-A1 | Respiratory Drug Condensation Aerosols and Methods of Making and Using Them | LTC4S, PTGER1, PTGES | TBXA2R 47/4885PTGDR 258/4885PTGIR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.